Studies have found that the IL-6/AKT signaling pathway promotes Mcl-1 expression in cholangiocarcinoma, which in turn mediates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) resistance in cholangiocarcinoma patients [36]. Here, IL6 is linked to cholangiocarcinoma.